Literature DB >> 16341573

Dense gas processing of micron-sized drug formulations incorporating hydroxypropylated and methylated beta-cyclodextrin.

Raffaella Mammucari1, Fariba Dehghani, Neil R Foster.   

Abstract

PURPOSE: Because of their importance in pharmaceutical applications, hydroxypropyl-beta-cyclodextrin and methyl-beta-cyclodextrin have been selected to study the formation of micronized complexes incorporating active pharmaceutical ingredients (APIs) and cyclodextrins (CDs) by dense gas (DG) processing.
METHODS: A single-step DG technique was used as an alternative to conventional methods for the manufacturing of API/CD complexes. The DG technology is highly attractive in the pharmaceutical industry because of its potential to generate micronized particles with controlled particle size distributions at moderate operating conditions. The effect of the aerosol solvent extraction system (ASES) processing on the dissolution performance of naproxen (NPX) was examined.
RESULTS: The CDs were produced as microspheres smaller than 3 microm. The coprecipitation of each CD with NPX resulted in the production of microparticles with enhanced dissolution rates.
CONCLUSIONS: The ASES was operated under mild conditions and generated micron-sized spherical particles that could be of particular interest in formulations for pulmonary delivery. Particular advantages of the technique are that (1) nontoxic solvents are used, and (2) it is suitable for the processing of thermally labile compounds. The proposed process can create opportunities to improve current administration routes and exploit novel delivery systems for drug formulations incorporating CDs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16341573     DOI: 10.1007/s11095-005-9094-7

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-03-01       Impact factor: 15.470

2.  Cyclodextrins in nasal drug delivery.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-03-01       Impact factor: 15.470

3.  Griseofulvin micronization and dissolution rate improvement by supercritical assisted atomization.

Authors:  E Reverchon; G Della Porta; A Spada; A Antonacci
Journal:  J Pharm Pharmacol       Date:  2004-11       Impact factor: 3.765

Review 4.  Cyclodextrins--enabling excipients: their present and future use in pharmaceuticals.

Authors:  D O Thompson
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1997       Impact factor: 4.889

Review 5.  Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery.

Authors:  R A Rajewski; V J Stella
Journal:  J Pharm Sci       Date:  1996-11       Impact factor: 3.534

Review 6.  Cyclodextrins: their future in drug formulation and delivery.

Authors:  V J Stella; R A Rajewski
Journal:  Pharm Res       Date:  1997-05       Impact factor: 4.200

7.  Utilization of supercritical carbon dioxide for complex formation of ibuprofen and methyl-beta-cyclodextrin.

Authors:  M Charoenchaitrakool; F Dehghani; N R Foster
Journal:  Int J Pharm       Date:  2002-06-04       Impact factor: 5.875

Review 8.  Medicinal applications of cyclodextrins.

Authors:  J Szejtli
Journal:  Med Res Rev       Date:  1994-05       Impact factor: 12.944

  8 in total
  3 in total

Review 1.  Supercritical Fluid Technology: An Emphasis on Drug Delivery and Related Biomedical Applications.

Authors:  Ranjith Kumar Kankala; Yu Shrike Zhang; Shi-Bin Wang; Chia-Hung Lee; Ai-Zheng Chen
Journal:  Adv Healthc Mater       Date:  2017-07-28       Impact factor: 9.933

2.  Formation of Rutin-β-Cyclodextrin Inclusion Complexes by Supercritical Antisolvent Precipitation.

Authors:  Paola Franco; Iolanda De Marco
Journal:  Polymers (Basel)       Date:  2021-01-13       Impact factor: 4.329

Review 3.  Supercritical Carbon Dioxide as a Green Alternative to Achieve Drug Complexation with Cyclodextrins.

Authors:  Mauro Banchero
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.